People with subretinal drusenoid deposits (SDD), a form of age-related macular degeneration, are more likely to have underlying heart damage as a result of heart failure or heart attacks, or other forms of cardiovascular disease associated with increased stroke risk.
Those who suffer from poor sleep quality, including daytime sleepiness, snoring, or getting too much or too little sleep, are at increased risk of developing glaucoma.
Administering a chemical compound called synthetic retinoids to the retina helped restore brain networks associated with vision and prompted the growth of two times more neurons, effectively restoring vision in adult mouse models of the genetic visual disorder LCA.
The loss of blood flow autoregulation caused by diabetes is the result of the disruption of the TRPV2 protein. Even in the absence of diabetes, disrupted blood flow autoregulation causes damage closely resembling that seen in diabetic retinopathy.
Determining the structure of vitronectin, a protein implicated in age-related macular degeneration and some neurodegenerative disorders, and using pressure to alter the protein shape may help in the development of new treatments for AMD.
A new study reports that a new gene therapy shows promise in treating dry age-related macular degeneration. The gene therapy, ophNdi1, directly targets mitochondrial function that is malfunctioning in AMD.
The discovery of new genetic signatures associated with age-related macular degeneration may lead to better diagnosis and treatment of the currently incurable vision disorder.
Researchers say Black patients are at greater risk of advanced vision loss than white patients following a diagnosis of primary open angle glaucoma.
Age-related changes in the retina may be driven by the loss of the pigment epithelium-derived factor protein. The findings could pave the way for the development of treatment for age-related macular degeneration and other age-related vision loss disorders.
The visual system adapts to the loss of photoreception by increasing sensitivity but simultaneously becomes deleteriously hyperactive. The findings could lead to new therapies to protect vision or reverse vision loss.